{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-004387","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2023-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.497165+00:00","generated_at":"2026-06-19T01:11:53.007640+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ARCA biopharma reports FY2022 net loss of $9.9M; cash $42.4M; strategic review ongoing","bullets":["Net loss $9.9M ($0.69/share) vs $19.3M ($1.39/share) in 2021; operating expenses down to $10.6M from $19.3M.","Cash and equivalents $42.4M at year-end; expected to fund operations through mid-2024.","R&D expenses fell to $4.7M from $13.8M due to completion of rNAPc2 Phase 2b trial; restructuring charges of $0.8M in Q3 2022.","Company engaged Ladenburg Thalmann to explore strategic alternatives including M&A; no timetable set."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-004387","json":"https://secwatch.observer/filing/0000950170-23-004387.json","markdown":"https://secwatch.observer/filing/0000950170-23-004387.md","text":"https://secwatch.observer/filing/0000950170-23-004387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000095017023004387/0000950170-23-004387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000095017023004387/abio-20230224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T01:11:53.007640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f25f161d48ec746e7945c42717d36f268c8a83b4","claim":"Oruka Therapeutics, Inc. reported the year ended December 31, 2022 results: net income $9.9 million, EPS $0.69 per basic and diluted share.","evidence_excerpt":"Net loss for the year ended December 31, 2022 was $9.9 million, or $0.69 per basic and diluted share, compared to $19.3 million, or $1.39 per basic and diluted share in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017023004387/0000950170-23-004387-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$9.9 million"},{"label":"EPS","value":"$0.69 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}